Repurposing Elemental Sulfur for Alzheimer Dementia (AD) Therapeutics: Role of Hydrogen Sulfide and ÃŽÂ’-Galactosidase

With the global increase in the aging population, the disease burden of Alzheimer Dementia (AD) has become a major public health challenge. Current AD drugs fail to modify the course of AD. In the mini-therapeutic perspective on AD, we highlight two promising targets: Homocysteine/Hydrogen sulfide signaling and lysosomal beta-galactosidase pathway in AD. We outline the rationale underlying our repurposing paradigm in translating Sulmedol (patented elemental sulfur) indicated for lactose intolerance, to promising drug lead for AD treatment. Our approach of designing Proof-of-concept biomarker-based placebo-controlled Phase II clinical trial of Sulmedol in early AD can accelerate AD therapeutics development.

Author(s): Chiu S, Khan AS, Terpstra K, Elias H, Khazaeipool Z, Carriere A, Cernovsky , Badmeav V, Husni M, Copen J, Shad M, Woodbury MF

Abstract | Full-Text | PDF

Share This Article